img
img
Jay Rughani
Bio + Health

Jay Rughani

Investing

More About Jay

Jay Rughani is an investing partner at Andreessen Horowitz where he specializes in healthcare technology, with a focus on AI and data products. He is inspired by entrepreneurs using software to accelerate clinical research, enable better care delivery, and increase affordability for patients. Jay helped to lead a16z’s investments in and is partnered with numerous ambitious companies, including Biodock, Freenome, Inductive, Komodo, Midstream, Orchestra, Pearl, Thatch, Thyme, Topography, Turquoise, and Valar.

Prior to joining a16z in 2018, Jay was an early team member at Flatiron Health (acquired by Roche for ~$2B). There, he helped to build some of the company’s first healthcare data & analytics products. He later led numerous commercial partnerships with large biopharma companies, smaller biotechs, and other healthcare organizations. Before Flatiron, he consulted for large healthcare and technology companies around the world at Deloitte, worked at a seed-stage multi-sided network startup called Dealermatch (acquired by Cox Enterprises), and co-founded an unsuccessful startup with his college roommate.

Jay graduated from Emory University with a degree in Mathematics & Economics and grew up mostly in Palm Harbor, FL, apart from a 3 year stint in boarding school in London, UK (not Hogwarts, regrettably).

Latest Content

  • Behind the Buy: Payors and Providers on AI Adoption
    Julie Yoo, Jay Rughani, Kris Tatiossian, and Olivia Webb

    This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider to be a good partnership.

  • Investing in Tennr New
    Kristina Shen, Zeya Yang, and Jay Rughani

    Tennr understands unstructured inputs, applying AI reasoning and decision-making to perform complex end-to-end workflows.

  • The New Drug Delivery Challenge: How Will Cures Reach Patients?
    Jay Rughani, Annie Collins, Jorge Conde, and Julie Yoo

    All this to say—it’s time to figure out how to access, pay for, and deliver curative therapies (amongst other high-cost, complex, specialty drugs), at scale. Let’s dive into the specific challenges that need to be surmounted to get this right.

  • Underestimating AI in Healthcare
    Daisy Wolf, Adela Tomsejova, Jay Rughani, and Vijay Pande

    100% of stock trades used to be made by humans. Today, 80% are made by computer algorithms. AI is about to bring a similar revolution to healthcare. Over the next few decades, at least half of the $4.3 trillion dollar American healthcare industry will be AI-driven.

  • AI: The Teammate Clinicians Need
    Jay Rughani, Colin Rom, Olivia Webb, Will Shrank, and Vijay Pande

    Our view is that 1) the latest advancements in AI offer a massive enablement opportunity to support our clinicians and 2) this can’t happen without the help of forward-thinking policymakers laying the infrastructure for AI-enabled care.

Load More
go to top